Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 22, 2017

Primary Completion Date

August 13, 2018

Study Completion Date

November 7, 2018

Conditions
Chronic Hepatitis C
Interventions
DRUG

SOF/VEL

400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily

Trial Locations (22)

1010

Auckland City Hospital, Grafton

5000

Royal Adelaide Hospital, Adelaide

28222

Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

41013

Hospital Universitario Virgen del Rocío, Seville

52173

The Chaim Sheba Medical Centre, Ramat Gan

64239

Tel Aviv Sourasky Medical Center, Tel Aviv

9103102

Shaare Zedek Medical Center, Jerusalem

Unknown

Kaye Edmonton Clinic, Edmonton

William Osler Health System- Brampton Civic Hospital, Brampton

BC V5Z 1M9

Gordon and Leslie Diamond Health Care Center, Vancouver General Hospital, UBC Division of Gastroenterology, Vancouver

ON L8V

Hamilton Health Sciences - McMaster University Medical Centre Site, Hamilton

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

H2X 3J4

Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montreal

08035

Hospital Universitari Vall d'Hebron, Barcelona

G12 0YN

Gartnavel General Hospital, Glasgow

E1 1BB

Barts Health NHS Trust, London

SE5 9RS

King's College Hospital, London

SW10 9NH

Chelsea and Westminster Hospital, London

W2 1NY

Imperial College Healthcare NHS Trust, London

NG5 1PB

Nottingham University Hospitals NHS Trust, Nottingham

PL6 8DH

Derriford Hospital, Plymouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT03036852 - Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease | Biotech Hunter | Biotech Hunter